Welcome to our dedicated page for Medtronic plc SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic plc (MDT) reported a strong first quarter of fiscal 2027, with net sales of $9.76 billion for the three months ended July 31, 2026, up from $8.58 billion a year earlier. Net income attributable to Medtronic rose to $1.47 billion from $1.04 billion, and diluted EPS increased to $1.14 from $0.81.
Growth was broad-based: Cardiovascular revenue reached $3.93 billion, Neuroscience $2.68 billion, Medical Surgical $2.28 billion, and Diabetes $0.84 billion, all above prior-year levels. Operating cash flow strengthened to $1.79 billion. Medtronic closed two Neuroscience acquisitions, Scientia Vascular and SPR Therapeutics, with purchase prices of $681 million and $654 million, adding technology-based and customer-related intangibles and increasing goodwill. The company ended the quarter with $1.69 billion in cash and $7.15 billion in available-for-sale debt securities, against $2.54 billion of current debt and $25.62 billion of long-term debt. Medtronic also detailed ongoing legal, environmental, and tax matters, including recent jury verdicts, and stated that related ultimate outcomes and losses remain uncertain.
Medtronic plc (MDT) reported strong Q1 fiscal 2027 results for the quarter ended July 31, 2026, with worldwide revenue of $9.756 billion, up 13.7% as reported and organically. The company estimates an extra fiscal week in Q1 benefited organic growth by approximately $570 million. GAAP diluted EPS was $1.14 and non-GAAP diluted EPS was $1.45, rising 40.7% and 15.1%, respectively.
Growth was broad-based: Cardiovascular revenue rose 19.5% to $3.927 billion, Neuroscience rose 10.3% to $2.678 billion, Medical Surgical rose 10.0% to $2.279 billion, and Diabetes grew 16.9% to $843 million. Free cash flow increased to $1.29 billion. Based on this performance, Medtronic raised FY27 organic revenue growth guidance to 7.25%–7.75% and non-GAAP EPS guidance to $5.94–$6.00, including an estimated neutral to 1% accretive foreign currency impact.
Medtronic plc (MDT) reported that executive officer Michael Marinaro, EVP, Pres MedSurg and Americas, had 1,084 Ordinary Shares withheld on 2026-08-20 to pay tax liabilities upon the vesting of previously awarded restricted stock units. After this tax-withholding disposition, he holds 116,336 Ordinary Shares directly.
Medtronic plc is asking shareholders at its October 15, 2026 Annual General Meeting in Galway, Ireland to vote on six key proposals, including electing twelve directors for one-year terms ending in 2027, ratifying PricewaterhouseCoopers LLP as independent auditor for fiscal 2027, approving executive compensation on an advisory basis, renewing the Board’s authority under Irish law to issue shares and to opt out of statutory pre-emption rights, and authorizing overseas market purchases of Medtronic ordinary shares. The Board recommends a “FOR” vote on all proposals.
For fiscal 2026, Medtronic generated $36.4 billion in revenue, up 8.4% reported and 5.8% organically versus fiscal 2025, with GAAP diluted EPS of $3.73 and non-GAAP diluted EPS of $5.53. GAAP operating profit rose 8.6%, non-GAAP operating profit rose 2.4%, and free cash flow reached $5.4 billion, the highest since 2022. Operating cash flow was $7.3 billion, and the company returned $4.2 billion to shareholders via dividends and net share repurchases.
Medtronic highlights strategic moves including the initial public offering of its Diabetes business, MiniMed, increased M&A and venture investments, and creation of new Board Growth and Operations Committees focused on portfolio, capital allocation, and margin improvement. The company reports serving over 82 million patients in FY26 and advancing sustainability, inclusion, and governance initiatives, with 17% female and 33% racial diversity among director nominees and an average director tenure of 7.42 years.
Medtronic plc reports that Chief Accounting Officer Denise L. Blomquist received new equity awards and had shares withheld for taxes. On August 3, 2026 she was granted 2,337 restricted stock units vesting 100% on the third anniversary of grant, 2,337 performance share units where each unit is a contingent right to one share with performance conditions measured on April 27, 2029 over a three-year performance period (issuing 2,337 shares at target performance, up to 5,609 at maximum, and possibly 0 if minimum metrics are not met), and 1,366 stock options exercisable at $86.68 per share, vesting 25% per year and expiring August 3, 2036. On July 31, 2026, 212 shares were withheld at $85.39 per share to pay taxes on previously vested restricted stock units, and her reported holdings include 136 shares acquired through dividend reinvestment since the prior report.
Medtronic plc reported insider equity activity by SVP, Chief HR Officer Walter Matthew R. On 2026-08-03 he received 5,769 restricted stock units that vest 100% on the third anniversary of grant, 14,421 performance share units that can settle for between 0 and 34,610 shares based on performance metrics over a three-year period with conditions measured through April 27, 2029, and stock options on 40,973 ordinary shares at 86.6800 per share expiring 2036-08-03, which become exercisable 25% per year beginning one year after grant. On 2026-07-31, 1,675 ordinary shares were withheld at 85.3900 per share to satisfy tax obligations upon vesting of previously reported restricted stock units.
Medtronic EVP & President, Neuroscience Thompson Kweli received equity compensation awards, including 17,306 performance share units, 49,167 stock options with a strike price of $86.68 expiring in 2036, and 6,923 restricted stock units vesting after three years. Separately, 1,739 shares were withheld to satisfy taxes on previously vested RSUs.
Medtronic plc reported that EVP, GC and Secretary Michelle Quinn received multiple equity awards on 2026-08-03. She was granted 6,346 restricted stock units that vest in full on the third anniversary of grant and now holds 26,721 ordinary shares directly. She also received 15,863 performance share units, which can result in between 0 and 38,071 ordinary shares based on performance through April 27, 2029, and 45,070 stock options with an exercise price of 86.6800 per share, vesting 25% annually and expiring on August 3, 2036.
Medtronic EVP & Chief Financial Officer Thierry Pieton reported equity awards dated August 3, 2026, including 11,537 restricted ordinary shares, 28,842 performance share units tied to three-year performance goals, and 81,945 stock options with an $86.68 exercise price expiring in 2036.